Navigation Links
Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
Date:2/22/2010

LOS ANGELES, Feb. 22 /PRNewswire/ -- Ritter Pharmaceuticals (www.ritterpharmaceuticals.com), a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24. The event will discuss topics regarding lactose intolerance and will be focused on answering questions such as the prevalence of lactose intolerance and health outcomes of diets which exclude dairy products.

Today, a significant concern among individuals, including healthcare providers, is that avoidance of dairy products leads to insufficient intake of calcium, vitamin D, and other nutrients. These deficiencies may cause weaker bone health, increased risk of bone fractures, osteoporosis and more serious issues such as hypertension, breast cancer, and colon cancer. Despite the risks associated with a dairy exclusion diet, 70% of the time physicians still recommend dairy avoidance to manage symptoms of lactose intolerance.(1)

"Making sure people eat adequate amounts of dairy is essential, but many lactose intolerant individuals do not choose to do so because of painful or uncomfortable symptoms," said Dennis Savaiano, Ph.D., Dean of the College of Consumer and Family Sciences, Foods and Nutrition at Purdue University and speaker at the upcoming NIH conference.

"Lactagen®, a product unlike any other on the market, is a dietary supplement program taken over 38 days, developed to help reduce symptoms of lactose intolerance," said Andrew Ritter, President and CEO of Ritter Pharmaceuticals, the makers of Lactagen®.  "Clinical data as well as our customers surveyed have shown that Lactagen® is nearly 80% effective at significantly reducing lactose intolerance symptoms."

Lactase supplements often prove to be ineffective or unreliable as reported in a recent study showing that only 26% of lactose intolerant individuals were satisfied with taking lactase supplements.(1)

About Ritter Pharmaceuticals

Ritter Pharmaceuticals is dedicated to helping individuals live a healthier and happier life style through improved digestion.  Ritter Pharmaceuticals focuses on the discovery, development and commercialization of innovative therapeutic treatments for gastrointestinal diseases and conditions.  One of these products is Lactagen®, a dietary supplement developed to help reduce symptoms of lactose intolerance.

(1) "Physicians' and Payors' Perception and Intended Use to Treat Lactose Intolerance." Study performed by Engage Health, June, 2008.

SOURCE Ritter Pharmaceuticals

Back to top

RELATED LINKS
http://www.ritterpharmaceuticals.com/
http://www.lactagen.com

'/>"/>

SOURCE Ritter Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
2. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
3. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
4. Transdel Pharmaceuticals Announces Management Reorganization
5. Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
6. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
7. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
8. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
9. Endo Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on February 22, 2010
10. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
11. ISTA Pharmaceuticals Announces 2010 Financial Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... poised to grow in 2017-2023. Various reasons for growth ... obese population, higher incidences of chronic diseases, high recovery ... mobility aid services. Medical lifting sling refers to ... with limited mobility. These slings connect to the lift ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/9/2016)... Woodland Hills, CA (PRWEB) , ... December 09, ... ... center for young adults, celebrated its 10th anniversary with the grand opening of ... Hills, California. The successful event spanned two days, December 2-3, and was attended ...
(Date:12/9/2016)... NJ (PRWEB) , ... December 09, 2016 , ... ... Founders Ball at The Pierre Hotel in New York, NY, on December 3rd, ... benefactors, dignitaries and physicians attended the annual event, which raised over $1 million ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
Breaking Medicine News(10 mins):